This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation
Lott, Ira T.,
Doran, Eric,
Nguyen, Vinh Q.,
Tournay, Anne,
Head, Elizabeth,
Gillen, Daniel L.
Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. There is a paucity of treatment trials for dementia in Down syndrome in comparison to Alzheimer disease in the general (non-Down syndrome) population. This 2-year randomized, double-blind, placebo-controlled trial assessed […]
Study protocol for the recreational stimulation for elders as a vehicle to resolve delirium superimposed on dementia (Reserve For DSD) trial
Kolanowski, Ann M.,
Fick, Donna M.,
Litaker, Mark S.,
Clare, Linda,
Leslie, Doug,
Boustani, Malaz
Background: Delirium is a state of confusion characterized by an acute and fluctuating decline in cognitive functioning. Delirium is common and deadly in older adults with dementia, and is often referred to as delirium superimposed on dementia, or DSD. Interventions that treat DSD are not well-developed because the mechanisms involved in its etiology are not […]
Pilot study of a nonpharmacological intervention for delirium superimposed on dementia
Kolanowski, Ann M.,
Fick, Donna M.,
Clare, Linda,
Steis, Melinda,
Boustani, Malaz,
Litaker, Mark
Delirium is a common neuropsychiatric syndrome that occurs most frequently in older adults with dementia and is referred to as delirium superimposed on dementia (DSD). Our aim in this pilot project was to demonstrate that implementation of cognitively stimulating activities is clinically feasible and has potential to reduce delirium severity and duration and functional loss […]
A randomized clinical trial of theory-based activities for the behavioral symptoms of dementia in nursing home residents
Kolanowski, Ann,
Litaker, Mark,
Buettner, Lin,
Moeller, Joyel,
Costa, Paul T., Jr.
Objectives: To test the main and interactive effects of activities derived from the Need-Driven Dementia-Compromised Behavior model for responding to behavioral symptoms in nursing home residents.; Design: Randomized double-blind clinical trial.; Setting: Nine community-based nursing homes.; Participants: One hundred twenty-eight cognitively impaired residents randomly assigned to activities adjusted to functional level (FL) (n=32), personality style […]
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies
Harrington, C.,
Sawchak, S.,
Chiang, C.,
Davies, J.,
Donovan, C.,
Saunders, A. M.,
Irizarry, M.,
Jeter, B.,
Zvartau-Hind, M.,
van Dyck, C. H.,
Gold, M.
Introduction: Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to any AChEI). An open-label extension study (REFLECT-4) assessed RSG XR long-term safety.; […]
Improving decision-making for feeding options in advanced dementia: a randomized, controlled trial
Hanson, Laura C.,
Carey, Timothy S.,
Caprio, Anthony J.,
Lee, Tae Joon,
Ersek, Mary,
Garrett, Joanne,
Jackman, Anne,
Gilliam, Robin,
Wessell, Kathryn,
Mitchell, Susan L.
Objectives: To test whether a decision aid improves quality of decision-making about feeding options in advanced dementia.; Design: Cluster randomized controlled trial.; Setting: Twenty-four nursing homes in North Carolina.; Participants: Residents with advanced dementia and feeding problems and their surrogates.; Intervention: Intervention surrogates received an audio or print decision aid on feeding options in advanced […]
Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer’s disease
Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer’s disease (AD).; Methods: Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm(2)]), […]